Cargando…

Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study

BACKGROUND: Apremilast, an oral phosphodiesterase 4 inhibitor, is approved in the European Union for the treatment of moderate-to-severe chronic plaque psoriasis in adult patients refractory or contraindicated to or intolerant of other systemic therapies. OBJECTIVES: The APPRECIATE study assessed ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Jonak, Constanze, Göttfried, Isolde, Perl-Convalexius, Sylvia, Gruber, Barbara, Schütz-Bergmayr, Martina, Vujic, Igor, Weger, Wolfgang, Schicher, Nikolaus, Semlin, Lydia, Hemetsberger, Margit, Cordey, Myriam, Sator, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909071/
https://www.ncbi.nlm.nih.gov/pubmed/36777399
http://dx.doi.org/10.1177/20406223231152785
_version_ 1784884490714218496
author Jonak, Constanze
Göttfried, Isolde
Perl-Convalexius, Sylvia
Gruber, Barbara
Schütz-Bergmayr, Martina
Vujic, Igor
Weger, Wolfgang
Schicher, Nikolaus
Semlin, Lydia
Hemetsberger, Margit
Cordey, Myriam
Sator, Paul
author_facet Jonak, Constanze
Göttfried, Isolde
Perl-Convalexius, Sylvia
Gruber, Barbara
Schütz-Bergmayr, Martina
Vujic, Igor
Weger, Wolfgang
Schicher, Nikolaus
Semlin, Lydia
Hemetsberger, Margit
Cordey, Myriam
Sator, Paul
author_sort Jonak, Constanze
collection PubMed
description BACKGROUND: Apremilast, an oral phosphodiesterase 4 inhibitor, is approved in the European Union for the treatment of moderate-to-severe chronic plaque psoriasis in adult patients refractory or contraindicated to or intolerant of other systemic therapies. OBJECTIVES: The APPRECIATE study assessed apremilast use in real-world practice and its clinical value to physicians and patients. APPRECIATE was a multinational, observational, retrospective, cross-sectional study. METHODS: Apremilast effectiveness at 6 (±1) months was assessed on the basis of psoriasis severity and health-related quality-of-life scores and treatment satisfaction using physician/patient-reported outcomes, respectively. We report the Austrian cohort of 72 patients. RESULTS: At 6 (±1) months, three-quarters of patients remained on apremilast, while physicians and patients reported treatment benefits across all psoriasis symptoms and manifestations. Of patients, the majority were satisfied with their treatment and achieved treatment goals considered most relevant. Patients’ and physicians’ perceptions of treatment effectiveness were aligned, and health-related quality-of-life scores indicated an improvement in the majority of patients. Apremilast tolerability was consistent with the known safety profile. CONCLUSIONS: Among psoriasis patients receiving apremilast in Austria, improvement in clinical outcomes were observed and satisfaction with apremilast treatment among patients and physicians was high. REGISTRATION: ClinicalTrials.gov NCT02740218
format Online
Article
Text
id pubmed-9909071
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-99090712023-02-10 Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study Jonak, Constanze Göttfried, Isolde Perl-Convalexius, Sylvia Gruber, Barbara Schütz-Bergmayr, Martina Vujic, Igor Weger, Wolfgang Schicher, Nikolaus Semlin, Lydia Hemetsberger, Margit Cordey, Myriam Sator, Paul Ther Adv Chronic Dis Original Research BACKGROUND: Apremilast, an oral phosphodiesterase 4 inhibitor, is approved in the European Union for the treatment of moderate-to-severe chronic plaque psoriasis in adult patients refractory or contraindicated to or intolerant of other systemic therapies. OBJECTIVES: The APPRECIATE study assessed apremilast use in real-world practice and its clinical value to physicians and patients. APPRECIATE was a multinational, observational, retrospective, cross-sectional study. METHODS: Apremilast effectiveness at 6 (±1) months was assessed on the basis of psoriasis severity and health-related quality-of-life scores and treatment satisfaction using physician/patient-reported outcomes, respectively. We report the Austrian cohort of 72 patients. RESULTS: At 6 (±1) months, three-quarters of patients remained on apremilast, while physicians and patients reported treatment benefits across all psoriasis symptoms and manifestations. Of patients, the majority were satisfied with their treatment and achieved treatment goals considered most relevant. Patients’ and physicians’ perceptions of treatment effectiveness were aligned, and health-related quality-of-life scores indicated an improvement in the majority of patients. Apremilast tolerability was consistent with the known safety profile. CONCLUSIONS: Among psoriasis patients receiving apremilast in Austria, improvement in clinical outcomes were observed and satisfaction with apremilast treatment among patients and physicians was high. REGISTRATION: ClinicalTrials.gov NCT02740218 SAGE Publications 2023-02-07 /pmc/articles/PMC9909071/ /pubmed/36777399 http://dx.doi.org/10.1177/20406223231152785 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Jonak, Constanze
Göttfried, Isolde
Perl-Convalexius, Sylvia
Gruber, Barbara
Schütz-Bergmayr, Martina
Vujic, Igor
Weger, Wolfgang
Schicher, Nikolaus
Semlin, Lydia
Hemetsberger, Margit
Cordey, Myriam
Sator, Paul
Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study
title Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study
title_full Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study
title_fullStr Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study
title_full_unstemmed Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study
title_short Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study
title_sort characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in austria – results the appreciate study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909071/
https://www.ncbi.nlm.nih.gov/pubmed/36777399
http://dx.doi.org/10.1177/20406223231152785
work_keys_str_mv AT jonakconstanze characteristicsandoutcomesofpatientswithpsoriasistreatedwithapremilastintherealworldinaustriaresultstheappreciatestudy
AT gottfriedisolde characteristicsandoutcomesofpatientswithpsoriasistreatedwithapremilastintherealworldinaustriaresultstheappreciatestudy
AT perlconvalexiussylvia characteristicsandoutcomesofpatientswithpsoriasistreatedwithapremilastintherealworldinaustriaresultstheappreciatestudy
AT gruberbarbara characteristicsandoutcomesofpatientswithpsoriasistreatedwithapremilastintherealworldinaustriaresultstheappreciatestudy
AT schutzbergmayrmartina characteristicsandoutcomesofpatientswithpsoriasistreatedwithapremilastintherealworldinaustriaresultstheappreciatestudy
AT vujicigor characteristicsandoutcomesofpatientswithpsoriasistreatedwithapremilastintherealworldinaustriaresultstheappreciatestudy
AT wegerwolfgang characteristicsandoutcomesofpatientswithpsoriasistreatedwithapremilastintherealworldinaustriaresultstheappreciatestudy
AT schichernikolaus characteristicsandoutcomesofpatientswithpsoriasistreatedwithapremilastintherealworldinaustriaresultstheappreciatestudy
AT semlinlydia characteristicsandoutcomesofpatientswithpsoriasistreatedwithapremilastintherealworldinaustriaresultstheappreciatestudy
AT hemetsbergermargit characteristicsandoutcomesofpatientswithpsoriasistreatedwithapremilastintherealworldinaustriaresultstheappreciatestudy
AT cordeymyriam characteristicsandoutcomesofpatientswithpsoriasistreatedwithapremilastintherealworldinaustriaresultstheappreciatestudy
AT satorpaul characteristicsandoutcomesofpatientswithpsoriasistreatedwithapremilastintherealworldinaustriaresultstheappreciatestudy